Search Results
Your search for ,WHo matches 20420 pages
Showing 20301 - 20350ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...
In the Clinic: Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...
ASCO 2013: No Increased Risk of Oral HPV Infections Reported in Long-term Partners of Patients with HPV-positive Oropharyngeal Cancers
Spouses and long-term partners of patients diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer were no more likely to test positive for oral HPV infection than people in the general population and have a low risk of HPV-related oropharyngeal cancer, according to the Human Oral...
ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma
Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...
ASCO 2013: Most U.S. Oncologists Report High Career Satisfaction, but Many Suffer Symptoms of Burnout
Although a majority of U.S. oncologists report satisfaction with their careers, many say they have experienced at least one symptom of burnout, according to a Mayo Clinic–led study released during the ASCO 2013 Annual Meeting (Abstract 6533). “Oncology can be a tremendously rewarding...
ASCO 2013: Anti–PD-1 Antibody Produces Durable, Ongoing Response in Patients with Advanced Melanoma
Preliminary results of an ongoing trial suggest that the anti–PD-1 antibody lambrolizumab has significant antitumor activity in patients with advanced melanoma and is well tolerated. The data were presented by Antoni Ribas, MD, PhD, Professor of Hematology/Oncology and Surgery, and Director...
ASCO 2013: Everolimus Significantly Delays Tumor Growth in Women with HER2-positive Advanced Breast Cancer
The addition of everolimus (Afinitor), an mTOR inhibitor, to trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival in women with HER2-positive advanced breast cancer, compared to treatment with placebo plus trastuzumab and vinorelbine, in the phase III BOLERO-3...
ASCO 2013: Pazopanib Maintenance Therapy Delays Relapse of Advanced Ovarian Cancer
A phase III clinical trial has found that pazopanib (Votrient), an oral multikinase inhibitor, extends disease-free survival by an average of 5.6 months, compared to placebo, in women with advanced ovarian cancer who had initial successful treatment with surgery and chemotherapy. “Our...
Experts Call for Breast Cancer Trials Aimed at Younger Patients
A lack of clinical trials aimed specifically at younger patients with breast cancer could be partly to blame for their poor survival rates, according to a study published in the Journal of the National Cancer Institute. Study Details The study analyzed 2,956 women diagnosed with breast cancer...
ASCO 2013: For Patients with Metastatic Pancreatic Cancer, Both Treatment and Survival Decrease with Advanced Age
A new study by researchers Fox Chase Cancer Center has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on,...
Ofatumumab plus Chlorambucil Improves Progression-free Survival in Patients with Previously Untreated CLL
In a phase III study, patients with previously untreated chronic lymphocytic leukemia (CLL) achieved an improvement in progression-free survival when treated with ofatumumab (Arzerra) in combination with chlorambucil vs chlorambucil alone. The study evaluated safety and efficacy of ofatumumab plus ...
FDA Approves Two Drugs, Companion Diagnostic Test for Advanced Skin Cancer
The U.S. Food and Drug Administration today approved two new drugs, dabrafenib (Tafinlar) and trametinib (Mekinist), for patients with advanced or unresectable melanoma, the most dangerous type of skin cancer. Dabrafenib, a BRAF inhibitor, is approved to treat patients with melanoma whose tumors...
Frequent Heartburn May Predict Cancers of the Throat and Vocal Cord
Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of...
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...
New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Physicians have more information to share with their patients about the benefits and risks of low-dose computed tomography (CT) lung cancer screening following the publication in the New England Journal of Medicine of the results of the first (of three planned) annual screening examinations from...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma
A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...
ASCO 2013: Surveillance Following Surgery Is Sufficient for Men with Stage I Seminoma
A long-term study of men with stage I seminoma, a common form of testicular cancer, suggests that surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of men who have undergone successful surgery for their cancer....
ASCO 2013: New Drug Targeting PI3K-delta Shows Strong Activity in Early Trial for High-risk Chronic Lymphocytic Leukemia
Results from a phase I study of a new oral targeted drug, idelalisib (GS-1101), show the agent has potential as a therapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). The drug produced rapid and long-lasting tumor shrinkage in half of the patients treated with...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
ASCO 2013: Standard-dose Radiation Is Superior to High-dose Radiation for Patients with Locally Advanced Stage III NSCLC Undergoing Chemotherapy
A phase III trial in patients with stage III non–small cell lung cancer (NSCLC) concluded that standard-dose radiotherapy (60 Gy) is safer and more effective than high-dose radiotherapy (74 Gy), extending survival by 9 months and causing fewer treatment-related deaths. While 60 Gy is already...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
ASCO 2013: Phase I Trial Suggests Ipilimumab and PD-1 Drug Nivolumab May Be Better Together than Alone for Advanced Melanoma
Results from a phase I study show that combination therapy with ipilimumab (Yervoy) and the investigational antibody drug nivolumab led to lasting tumor shrinkage in approximately half of patients with aggressive, advanced melanoma. The results will be presented at the 2013 ASCO Annual Meeting in...
FDA Approves Expanded Use for Erlotinib, Companion Diagnostic to Detect Genetic Mutations in NSCLC
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test, a companion diagnostic for erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10% of...
Study: Popular Diabetes Drug Does Not Improve Survival Rates after Cancer
Despite previous scientific studies suggesting that the diabetes drug metformin has anticancer properties, a new, first-of-its-kind study from Women’s College Hospital in Toronto has found the drug may not actually improve survival rates after breast cancer in certain patients. The study,...
Blocking a Single Gene Renders Tumors Less Aggressive, Johns Hopkins Researchers Find
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called “master regulator” gene may be the key to...
Bladder Cancer Could Recur despite Bladder Removal
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests. The 5-year international study led by researchers at UT Southwestern validates the use of a marker...
Emil ‘Tom’ Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Radiation Therapy May Be Unnecessary for Postmenopausal Patients with Early-stage Breast Cancer after Conservative Surgery
Postmenopausal women aged 55 to 75 with early-stage breast cancer can be safely treated with breast-conserving surgery without postoperative radiation therapy, according to a double-arm, prospective, randomized study presented this week at the American Society of Breast Surgeons Annual Meeting. The ...
Daratumumab Receives Breakthrough Therapy Designation in Multiple Myeloma
FDA has granted daratumumab breakthrough therapy designation for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or who are double refractory to a proteasome inhibitor and...
Women Smokers May Have Greater Risk for Colon Cancer Than Men
Smoking increased the risk for developing colon cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “Globally, during the last 50...
Selective Estrogen Receptor Modulators Reduce Breast Cancer Rates by More Than a Third in Women at High Risk
Tamoxifen and three similar drugs reduce breast cancer incidence by 38% in women at an increased risk of the disease according to a Cancer Research UK study published in The Lancet today. In the most comprehensive study to date scientists calculate that one breast cancer would be prevented for...
Researchers Identify New Pathway, Enhancing Tamoxifen to Tame Aggressive Breast Cancer
Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center (URMC) team has shown how to exploit tamoxifen’s secondary activities so that it might work on more aggressive breast...
Obese Men with Benign Biopsy at High Risk for Prostate Cancer
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the...
Delays in Diagnosis Worsen Outlook for Minority, Uninsured Pediatric Retinoblastoma Patients, Study Finds
When retinoblastoma is diagnosed in racial and ethnic minority children whose families don't have private health insurance, it often takes a more invasive, potentially life-threatening course than in other children, probably because of delays in diagnosis, researchers at Dana-Farber/Children's...
Majority of Children Readmitted to Hospital Following Stem Cell Transplant
Nearly two-thirds of children receiving stem cell transplants returned to the hospital within 6 months for treatment of unexplained fevers, infections, or other problems, according to a study performed at Dana-Farber/Children’s Hospital Cancer Center in Boston. Children who received donor...
Chernobyl Follow-up Study Finds High Survival Rate among Young Thyroid Cancer Patients
More than a quarter of a century after the Chernobyl nuclear disaster, many children and teenagers who developed thyroid cancer due to radiation are in complete or near remission, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology ...
Bipartisan Group of 124 Lawmakers Express Concern That Medicare Cuts to Life-sustaining Cancer Drugs Threaten Patient Care
The American Society of Clinical Oncology, Community Oncology Alliance, ION Solutions, and The US Oncology Network today commended a bipartisan group of 124 lawmakers in the U.S. House of Representatives who sent a letter to the Centers for Medicare and Medicaid Services (CMS) expressing concern...
Study to Treat Deadly Form of Thyroid Cancer Shows Promise, Mayo Clinic Says
A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, said researchers at Mayo Clinic in Florida. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed...
Pharmacyclics Completes Enrollment of Phase III Ibrutinib CLL Study and Phase II Ibrutinib MCL Study
Pharmacyclics, Inc, announced today that the enrollment target of 350 patients for RESONATE, its phase III study using ibrutinib monotherapy vs ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, was achieved on April 3, 2013. As...
Few Breast Cancer Survivors Maintain Adequate Physical Activity Despite Benefits
Breast cancer survivors are among the women who could most benefit from regular physical activity, yet few meet national exercise recommendations during the 10 years after being diagnosed, according to a study by researchers at Fred Hutchinson Cancer Research Center. Prior studies and available...
Cryoablation Spot Treats Cancer in the Lung, Extends Survival
Frozen balls of ice can safely kill cancerous tumors that have spread to the lungs, according to the first prospective multicenter trial of cryoablation. The results were presented on April 14, 2013, at the Society of Interventional Radiology’s 38th Annual Scientific Meeting in New Orleans....
Mammogram Tool Improves Some Breast Cancer Detection but Also Increases False Alarms
A costly and widely used mammography add-on increases detection of noninvasive and early-stage invasive breast cancer but also makes more mistakes than mammography alone, researchers from UC Davis and the University of Washington have found. A new study shows that computer-assisted detection (CAD) ...
Asbestos Exposure, Asbestosis, and Smoking Combined Greatly Increase Lung Cancer Risk
The chances of developing lung cancer associated with asbestos exposure, asbestosis, and smoking are dramatically increased when these three risk factors are combined, and quitting smoking significantly reduces the risk of developing lung cancer after long-term asbestos exposure, according to a new ...
NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma
Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results. Until now, most standard treatment approaches for patients with this type of...
